BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16374613)

  • 1. Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.
    Gückel B; Rentzsch C; Nastke MD; Marmé A; Gruber I; Stevanović S; Kayser S; Wallwiener D
    J Cancer Res Clin Oncol; 2006 Apr; 132(4):265-74. PubMed ID: 16374613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.
    Jerome KR; Domenech N; Finn OJ
    J Immunol; 1993 Aug; 151(3):1654-62. PubMed ID: 8393050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.
    Nagorsen D; Scheibenbogen C; Schaller G; Leigh B; Schmittel A; Letsch A; Thiel E; Keilholz U
    Int J Cancer; 2003 Jun; 105(2):221-5. PubMed ID: 12673683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
    Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
    Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells.
    Saito H; Dubsky P; Dantin C; Finn OJ; Banchereau J; Palucka AK
    Breast Cancer Res; 2006; 8(6):R65. PubMed ID: 17129372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antibody responses to breast carcinoma associated mucins using synthetic peptide constructs as immunogens.
    Denton G; Sekowski M; Price MR
    Cancer Lett; 1993 Jul; 70(3):143-50. PubMed ID: 7689035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
    Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
    Tsang KY; Palena C; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2004 Mar; 10(6):2139-49. PubMed ID: 15041735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.
    Ioannides CG; Fisk B; Jerome KR; Irimura T; Wharton JT; Finn OJ
    J Immunol; 1993 Oct; 151(7):3693-703. PubMed ID: 7690810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.
    Kilger E; Pecher G; Schwenk A; Hammerschmidt W
    J Gene Med; 1999; 1(2):84-92. PubMed ID: 10738572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors.
    Agrawal B; Reddish MA; Longenecker BM
    J Immunol; 1996 Sep; 157(5):2089-95. PubMed ID: 8757331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells.
    Pecher G; Finn OJ
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1699-704. PubMed ID: 8643693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice.
    Gerloni M; Castiglioni P; Zanetti M
    J Immunol; 2005 Nov; 175(10):6551-9. PubMed ID: 16272309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
    Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
    Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
    Kayser S; Watermann I; Rentzsch C; Weinschenk T; Wallwiener D; Gückel B
    J Cancer Res Clin Oncol; 2003 Jul; 129(7):397-409. PubMed ID: 12836015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
    Kida A; Mizukoshi E; Tamai T; Terashima T; Kitahara M; Arai K; Yamashita T; Fushimi K; Honda M; Kaneko S
    Liver Int; 2018 Nov; 38(11):2040-2050. PubMed ID: 29790264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
    Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
    Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.